@entity310 antagonists and XXXX for the management of gastrointestinal Beh  et's syndrome refractory to the conventional treatment modalities: a case series and review of the literature.

@entity1 @entity295 @entity500 @entity310 @entity2816 @entity344 @entity4184 @entity2983
OBJECTIVES: Gastrointestinal involvement of Beh  et's syndrome is usually treated with glucocorticoids, @entity2983 compounds and @entity500 . However, some @entity1 are refractory to these conventional therapy modalities. In this paper we report our experience on 13 @entity1 with @entity344 of Beh  et's syndrome who were refractory to the conventional therapy and who were treated with @entity310 antagonists and/or @entity2816 . METHODS: We reviewed the charts of our Beh  et's syndrome @entity1 with @entity344 and identified those who were treated with @entity310 antagonists and/or @entity2816 . Demographic features, previous and concomitant drugs, previous surgery, time to remission and duration of remission were tabulated. We also performed a systematic review of publications on @entity344 of Beh  et's syndrome @entity1 treated with @entity310 antagonists and/or @entity2816 . RESULTS: Among our 64 @entity1 with @entity344 of Beh  et's syndrome, we identified 13 (20%) (7 @entity1 , 6 @entity1 , mean age 27.4    9.4) who had been treated with @entity310 antagonists and/or @entity2816 . Their previous medications were glucocorticoids (13/13), @entity500 (13/13), @entity2983 derivatives (3/13) and @entity4184 (1/13). Clinical and endoscopic remission was obtained in 10 @entity1 . One @entity1 died with @entity295 . The systematic literature search revealed 91 cases who had used @entity310 antagonists and 15 who had used @entity2816 . Among the @entity1 who had received @entity310 antagonists, clinical remission was obtained in 47/91 @entity1 (51%), while endoscopic remission was observed in 21/46 (45%) who had a control colonoscopy. CONCLUSIONS: One fifth of our Beh  et's syndrome @entity1 with @entity344 were refractory to conventional treatment modalities. Remission was obtained with @entity310 antagonists and/or @entity2816 in about 75% of the cases.
